Objective: Enoxaparin (Clexane) is a low molecular weight heparin with a molecular weight of around 4500D. It is a blood thinner used to treat pulmonary embolism, Deep vein thrombosis, unstable angina, non-ST elevated myocardial infarction and STsegment elevation myocardial infarction. T his project is designed to evaluate the most widely used Low molecular weight heparin (LMWH), enoxaparin in patients with Acute Coronary Syndrome (ACS) based on prescriptions evaluation. Methods: Prescriptions were collected from different health institutes and were evaluated on the basis of Market Share, MIP data-competitors, MIP data- indication, and on MIP data- specialty. The study included both male and female patients of age ranging between 50-70 years. The results reflect the prescription patterns of enoxaparin (Clexane) by evaluating 73 prescriptions from major cardiovascular hospitals in Pakistan between February 2008 and October 2008. Results: The prescription pattern showed that physicians in Pakistan have a tendency of prescribing enoxaparin with other drugs. The results also showed that patients were prescribed multiple anti-coagulants concomitantly, including enoxaparin and aspirin. Conclusion: Overall, the analysis of anti-coagulants has indicated that enoxaparin is the drug of choice for the treatment of ACS.